Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580

被引:22
作者
Sumida, T [1 ]
Otani, H [1 ]
Kyoi, S [1 ]
Okada, T [1 ]
Fujiwara, H [1 ]
Nakao, Y [1 ]
Kido, M [1 ]
Imamura, H [1 ]
机构
[1] Kansai Med Univ, Dept Thorac & Cardiovasc Surg, Cardiovasc Res Ctr, Moriguchi, Osaka 5708507, Japan
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2005年 / 288卷 / 06期
关键词
necrosis; contractility;
D O I
10.1152/ajpheart.01183.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
p38 MAP kinase activation is known to be deleterious not only to mitochondria but also to contractile function. Therefore, p38 MAP kinase inhibition therapy represents a promising approach in preventing reperfusion injury in the heart. However, reversal of p38 MAP kinase-mediated contractile dysfunction may disrupt the fragile sarcolemma of ischemic-reperfused myocytes. We, therefore, hypothesized that the beneficial effect of p38 MAP kinase inhibition during reperfusion can be enhanced when contractility is simultaneously blocked. Isolated and perfused rat hearts were paced at 330 rpm and subjected to 20 min of ischemia followed by reperfusion. p38 MAP kinase was activated after ischemia and early during reperfusion (<30 min). Treatment with the p38 MAP kinase inhibitor SB-203580 (10 mu M) for 30 min during reperfusion, but not the c-Jun NH2-terminal kinase inhibitor SP-600125 (10 mu M), improved contractility but increased creatine kinase release and infarct size. Cotreatment with SB-203580 and the contractile blocker 2,3-butanedione monoxime (BDM, 20 mM) or the ultra-short-acting beta-blocker esmorol (0.15 mM) for the first 30 min during reperfusion significantly reduced creatine kinase release and infarct size. In vitro mitochondrial ATP generation and myocardial ATP content were significantly increased in the heart cotreated with SB-203580 and BDM during reperfusion. Dystrophin was translocated from the sarcolemma during ischemia and reperfusion. SB-203580 increased accumulation of Evans blue dye in myocytes depleted of sarcolemmal dystrophin during reperfusion, whereas cotreatment with BDM facilitated restoration of sarcolemmal dystrophin and mitigated sarcolemmal damage after withdrawal of BDM. These results suggest that treatment with SB-203580 during reperfusion aggravates myocyte necrosis but concomitant blockade of contractile force unmasks cardioprotective effects of SB-203580.
引用
收藏
页码:H2726 / H2734
页数:9
相关论文
共 45 条
[1]   Role of mitogen-activated protein kinases in ischemia and reperfusion injury - The good and the bad [J].
Abe, J ;
Baines, CP ;
Berk, BC .
CIRCULATION RESEARCH, 2000, 86 (06) :607-609
[2]   FLOW CYTOMETRIC ANALYSIS OF ISOLATED ADULT CARDIOMYOCYTES - VINCULIN AND TUBULIN FLUORESCENCE DURING METABOLIC INHIBITION AND ISCHEMIA [J].
ARMSTRONG, SC ;
GANOTE, CE .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1992, 24 (02) :149-162
[3]   Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death [J].
Barancik, M ;
Htun, P ;
Strohm, C ;
Kilian, K ;
Schaper, W .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (03) :474-483
[4]   Molecular and cellular mechanisms of myocardial stunning [J].
Bolli, R ;
Marbán, E .
PHYSIOLOGICAL REVIEWS, 1999, 79 (02) :609-634
[5]   Mitochondria in apoptosis of ischemic heart [J].
Borutaite, V ;
Brown, GC .
FEBS LETTERS, 2003, 541 (1-3) :1-5
[6]   Acute p38 MAPK activation decreases force development in ventricular myocytes [J].
Chen, Y ;
Rajashree, R ;
Liu, QH ;
Hofmann, P .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2003, 285 (06) :H2578-H2586
[7]   p38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells [J].
Cheng, AW ;
Chan, SL ;
Milhavet, O ;
Wang, SQ ;
Mattson, MP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (46) :43320-43327
[8]   Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinase-dependent mechanism [J].
Folden, DV ;
Gupta, A ;
Sharma, AC ;
Li, SY ;
Saari, JT ;
Ren, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (07) :1310-1316
[9]   Stress-activated protein kinase phosphorylation during cardioprotection in the ischemic myocardium [J].
Fryer, RM ;
Patel, HH ;
Hsu, AK ;
Gross, GJ .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2001, 281 (03) :H1184-H1192
[10]   ISCHEMIA AND THE MYOCYTE CYTOSKELETON - REVIEW AND SPECULATION [J].
GANOTE, C ;
ARMSTRONG, S .
CARDIOVASCULAR RESEARCH, 1993, 27 (08) :1387-1403